๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Onset of seizures as a poor indicator of longevity in people with down syndrome and dementia

โœ Scribed by Dr. V. P. Prasher; J. A. Corbett


Publisher
John Wiley and Sons
Year
1993
Tongue
English
Weight
375 KB
Volume
8
Category
Article
ISSN
0885-6230

No coin nor oath required. For personal study only.

โœฆ Synopsis


An association between Down syndrome and dementia of Alzheimer type is well established. This study demonstrates that late onset seizures in people with Down syndrome are a strong indicator of a dementing process. Further, late onset seizures in people with Down syndrome may be used as a prognostic indicator, indicating life expectancy of less than a further 2 years, probable death within 3 years and death almost invariably within 5 years of onset.

KEY woms-Down syndrome, dementia, seizures, longevity.

During the latter half of this century the life expectancy of people with Down syndrome (DS) has increased considerably (Oliver and Holland, 1986;Prasher, 1992). Many individuals will live into middle age and beyond (Baird and Sadovnick, 1988). However, above the age of 40 years there is a dramatic rise in the mortality rate for individuals compared to those below this age (Thase, 1982). This is in part related to the increase in neuropathological changes of Alzheimer disease in the brain and the onset of clinical dementia (Mann, 1988;Prasher, 1993;Prasher and Krishnan, 1993).

Studies of longevity in adults without mental handicap but with the presence of dementia suggest longevity may range from a few months to several decades, with an average life span from time of diagnosis to death of 7 years (Sjogren et al., 1952). Between 25 and 30% live over 10 years, and some may live as long as 20 years (Corsellis, 1976; Katzman et al., 1978). For people with DS, Prasher and Krishnan (1993) recently reviewed the published case reports of 98 people with DS with respect to the age of onset and duration of clinical dementia. They found a mean age of onset of 5 1.7 years (range 31-68 years) and a mean duration of dementia of 6 years (range 0.5-21 years).


๐Ÿ“œ SIMILAR VOLUMES


Visual evoked potential in the diagnosis
โœ Dr. V. P. Prasher; V. H. R. Krishnan; A. Blake; D. J. Clarke; J. A. Corbett ๐Ÿ“‚ Article ๐Ÿ“… 1994 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 447 KB ๐Ÿ‘ 1 views

## Abstract The diagnosis of dementia in people with Down syndrome (DS) remains controversial. In this study DS patients who had a diagnosis of clinical dementia according to modified DSMโ€IIIโ€R criteria were assessed using the flash (P2) and patternโ€reversal (P100) visual evoked potential (VEP). Ab

II. Ascertainment of a population of peo
โœ Kirstie Woodburn; Eve Johnstone ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 191 KB ๐Ÿ‘ 2 views

Objective. The aim of the case ascertainment for the study was to identify as near complete as possible a population of patients with presenile dementia who had been identiยฎed by hospital contact within a deยฎned period of time, and who were currently alive, in the Lothian area. It did not aim to est

I. Measuring the decline of a population
โœ Kirstie Woodburn; Eve Johnstone ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 205 KB ๐Ÿ‘ 2 views

Objective. To seek dierences in the pattern of decline between groups of patients with early-onset dementia of varying aetiologies (clinically deยฎned) on the basis of the investigation of their dierent clinical proยฎles. Design. A cohort of 126 live patients with dementia diagnosed before the age of

Significant effect of APOE epsilon 4 gen
โœ V. P. Prasher; S. G. Sajith; S. D. Rees; A. Patel; S. Tewari; N. Schupf; W. B. Z ๐Ÿ“‚ Article ๐Ÿ“… 2008 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 82 KB ๐Ÿ‘ 1 views

## Abstract ## Objective Virtually all adults with Down syndrome (DS) have neuropathological manifestations of Dementia in Alzheimer's disease (DAD) but not all develop clinical psychopathology. The effect of allelic variants of Apolipoprotein (APOE) gene in development and progression of DAD and

Utility of blasts with a clear halo arou
โœ Iwao Emura; Takaaki Chou; Yosuke Imai; Toshio Kakihara; Keiko Asami; Makoto Nait ๐Ÿ“‚ Article ๐Ÿ“… 2000 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 137 KB ๐Ÿ‘ 2 views

This study was designed to evaluate the utility of blasts with a clear halo around their nucleoli (BCHN) as a predictive indicator of disease progression in myelodysplastic syndromes (MDSs) and aplastic anemia (AA). Bone marrow aspirates from 75 patients with MDSs and 18 with AA were fixed in 95% et